Twelfth

SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong an

Retrieved on: 
Tuesday, January 11, 2022 - 7:55am

The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".

Key Points: 
  • The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".
  • In addition, SN1011, a key product of the Company, completed its phase I last subject last visit in China in July last year.
  • That reflects the capital market's recognition of the value, management and growth potential of the Company and is a great encouragement to the Company.
  • The selection of the "6th Hong Kong Golden Stocks Awards" was jointly organized by Zhitongcaijing.com, a leading Hong Kong and US stock information platform in China, with RoyalFlush Finance and China Galaxy Securities.

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

Retrieved on: 
Tuesday, November 30, 2021 - 11:50am

The patients currently in screening will be randomized by end of December 2021, given eligibility criteria are met.

Key Points: 
  • The patients currently in screening will be randomized by end of December 2021, given eligibility criteria are met.
  • SM03 (Suciraslimab), a potential global first-in-target anti-CD22 monoclonal antibody for the treatment of RA and potentially for the treatment of other immunological diseases, is currently in Phase III clinical trials in China.
  • The Phase III clinical trial is a multi-center, randomized, double-blind, placebo-controlled, parallel group study to confirm the clinical efficacy and long-term safety in active RA patients receiving methotrexate (MTX).
  • The efficacy and safety of Suciraslimab was previously evaluated in a phase II clinical study in moderate-to-severely active RA patients.

SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health

Retrieved on: 
Friday, November 26, 2021 - 9:26am

With the theme of "Shaping a Resilient and Sustainable Future", the Inaugural ASGH was held at the Convention Hall of Hong Kong Convention and Exhibition Centre and synchronized online.

Key Points: 
  • With the theme of "Shaping a Resilient and Sustainable Future", the Inaugural ASGH was held at the Convention Hall of Hong Kong Convention and Exhibition Centre and synchronized online.
  • Doing innovative research in Hong Kong enjoys advantages such as legal protection and patenting system, which will facilitate the companies to get licensed with other collaborators.
  • Dr. Shui On LEUNG said, "It is a great honour to attend the Inaugural ASGH on behalf of the Company.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

Retrieved on: 
Friday, September 17, 2021 - 12:40am

This Phase I clinical trial is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and recommended Phase II dose of SN1011 in the treatment of autoimmune disease.

Key Points: 
  • This Phase I clinical trial is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and recommended Phase II dose of SN1011 in the treatment of autoimmune disease.
  • Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases.
  • Sinovent is a global biopharmaceutical company focused on discovery, development, and commercialization of innovative medicines to address significant unmet clinical needs.
  • Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development.

Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases

Retrieved on: 
Thursday, September 16, 2021 - 11:30pm

The agreement will also include full technology transfer of the current manufacturing process to Everest to support future development and commercialization.

Key Points: 
  • The agreement will also include full technology transfer of the current manufacturing process to Everest to support future development and commercialization.
  • "Chronic kidney disease is a leading public health problem worldwide and primary glomerular disease is a common cause of renal damage.
  • Sinovent is a global biopharmaceutical company focused on discovery, development, and commercialization of innovative medicines to address significant unmet clinical needs.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.